Aceclofenac, a Preferential COX-2 Inhibitor
- Appraisal of Safety and Tolerability

Anu Grover¹, Eknath Pawar², G. K. Singh³, Ashok Gupta⁴, Anil Pareek⁵, Rujul Desai⁶, Indranil Purkait⁷

¹Deputy General Manager, Medical Affairs, Ipca Laboratories Ltd, Mumbai, Maharashtra, India. ²Professor & HOD, Department of Orthopedics, Grant Government Medical College & J J Group of Hospitals, Mumbai, Maharashtra, India. ³HOD, Era Medical College, Lucknow, Uttar Pradesh, India. ⁴Senior Orthopaedic Surgeon, Dharam Hospital, Chandigarh, India. ⁵President Medical Affairs & Clinical Research, Ipca Laboratories Ltd, Mumbai, Maharashtra, India. ⁶Assistant Manager, Medical Affairs, Ipca Laboratories Ltd, Mumbai, Maharashtra, India. ⁷Senior General Manager, Medical Affairs, Ipca Laboratories Ltd, Mumbai, Maharashtra, India.

ABSTRACT

BACKGROUND
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications to reduce inflammation and pain in clinical practice. The main concern with their use is gastrointestinal and cardiovascular side effects due to inhibition of gastroprotective prostaglandins and imbalance of prostacyclin and thromboxane respectively. NSAIDs function by inhibiting the cyclooxygenase (COX) enzymes. Evidence shows the occurrence of these side effects even with their short term use. Development of NSAID with a goal of superior or similar efficacy but with lower incidences of side effects resulted in the introduction of aceclofenac. Classified as a preferential COX-2 inhibitor, aceclofenac inhibits the COX-2 enzyme preferentially (97%) as compared to COX-1 (46%). Lesser inhibition of the COX-1 enzyme results in lower incidences of GI side effects. Also, due to preferential COX-2 selectivity, aceclofenac balances vascular homeostasis and thus has minimal CV risk. The diversity of COX-1 and COX-2 selectivity in NSAIDs has proven clinically important. Encouraging clinical evidence shows that aceclofenac has a favourable safety profile amongst NSAIDs. Our goal in this manuscript is to give a narrative review of clinical evidence of aceclofenac’s safety and tolerability. Based on the data, we can conclude that aceclofenac is an effective analgesic in both acute and chronic inflammatory conditions, with a comparatively low risk of gastrointestinal and cardiovascular adverse effects. This favourable tolerability profile of the drug reflects a reduction in cost associated with adverse events management, from both patient’s and healthcare provider’s perspectives.

KEY WORDS
Non-Steroidal Anti-Inflammatory Drugs, Pain, Inflammation, NSAID, COX Enzyme, Preferential COX-2 Inhibitor, Aceclofenac, Gastrointestinal Safety, Cardiac Safety.

Corresponding Author:
Dr Anu Grover, Deputy General Manager, Medical Affairs, Ipca Laboratories Ltd, Mumbai, Maharashtra, India. E-mail: anu293@gmail.com

DOI: 10.14260/jemds.v11i7.148

How to Cite This Article:


Copyright © 2022 Anu Grover et al, This is an open access article distributed under Creative Commons Attribution License [Attribution 4.0 International (CC BY 4.0)].
Inflammation was one of the earliest diseases to be recognized and classified based on cardinal indications. Hippocrates, a Greek physician, treated inflammation around 3500 (400 B.C.)[1] Later, Bayer introduced aspirin as the first non-steroidal anti-inflammatory drug in 1899. The exact mechanism of action of aspirin introduced in 1960s aided the development of novel anti-inflammatory drugs.[2] Non-steroidal anti-inflammatory drugs (NSAIDs) are the cornerstone of pain management in acute, chronic and other painful inflammatory conditions.[3] Approximately 70% of people, especially in the age group of 65 years or older use NSAIDs at least once per week.[4] The involvement of the cyclooxygenase (COX) enzyme in the inflammatory process is the primary target of NSAIDs.[5] COX enzyme exists in its two isoforms: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is responsible for the formation of gastroprotective prostaglandins (PGs) while COX-2 forms inflammatory PGs. Based on the selectivity of COX enzyme inhibition, three classes of NSAIDs have emerged; non-selective COX inhibitors also called traditional NSAIDs, selective COX-2 inhibitors, and preferential COX-2 inhibitors. Traditional/Non-selective COX inhibitors such as ibuprofen, diclofenac, piroxicam, ketorolac and ketoprofen, hinder both COX-1 and COX-2 enzymes resulting in the inhibition of gastroprotective prostaglandins, thereby causing gastrointestinal (GI) side effects. This limitation of non-selective NSAIDs leads to a shift in focus to selective COX-2 inhibitors, referred to as COXIBs like celecoxib and etoricoxib. They have shown promising anti-inflammatory activity with reduced GI side effects.[6] However, there has been a concern about the cardiac safety of COXIBs. Two well-known COXIBs; rofecoxib and valdecoxib were banned or withdrawn from the market by US FDA due to their cardiac adverse effects. Rofecoxib was withdrawn in 2004 from the market due to an increased risk of myocardial infarction[7] and later in the same year, a black-box warning was issued for valdecoxib due to its increased cardiovascular (CV) risk. Later, the drug was withdrawn by the manufacturer.[8]

Development of NSAID with a goal of improved efficacy and lower incidences of GI as well as cardiac side effects resulted in the introduction of aceclofenac. Aceclofenac, categorized as a preferential COX-2 inhibitor, has a potent anti-inflammatory action. Several clinical studies have shown its efficacy and safety profile better in comparison with other NSAIDs. Our goal in this manuscript is to give a narrative review of clinical evidence of aceclofenac’s safety and tolerability.[9]

Background of Aceclofenac
Aceclofenac, a phenylacetic acid derivative, was patented in 1983 and approved for medical use in 1992 in Spain. Since then, it is used worldwide as an effective therapeutic drug in various painful inflammatory conditions, acute as well as chronic.[10] Its efficacy is well established in acute musculoskeletal pain, dental pain, low back pain, arthritis and other painful conditions encountered in clinical practice.[11] It is a potent inhibitor of COX, a key enzyme in the synthesis of inflammatory prostaglandins and thromboxane, with selectivity for COX-2 over COX-1 isofrom. NSAIDs with a preferential COX-2 inhibition over COX-1 have less GI toxicity and fewer cardiac side effects.[22,24] Aceclofenac showed 46% inhibition of COX-1 and 97% of COX-2 inhibition.[23] COX-2 selective, partially selective, or non-selective oral NSAIDs are equally effective in controlling pain. Thus, drug choice is dictated by their safety profile, according to different risk factors, and patients’ concomitant diseases and medical conditions. The benefit-risk balance of individual NSAIDs is mainly driven by their GI and CV safety profiles.[25]

Safety and Tolerability Profile of Aceclofenac

Gastrointestinal Safety
NSAID-related gastrointestinal disorders represent the 2nd largest life-threatening factor after a primary illness in patients with arthritis. NSAIDs are linked to a variety of GI side effects, including acute and severe GI symptoms. These symptoms range from superficial mucosal injury/erosions, GI irritation, dyspepsia, and abdominal pain, to the development of gastric or duodenal ulcers. GI complications such as bleeding, perforation, and blockage are severe forms of NSAID-induced adverse effects. The latter may even result in hospitalization or death[9] The prevalence of NSAID induced GI side effects is shown in Figure 1.

NSAID gastropathy is of great clinical concern and NSAID with a better safety profile and high efficacy is preferred. Aceclofenac is shown to be well tolerated with a good safety profile in various clinical trials and post-marketing surveillance experience. Commonly reported GI events of aceclofenac, with incidences below 5%, include nausea, diarrhoea, flatulence, gastritis, constipation, vomiting and ulcerative stomatitis. In terms of physician and patient rating of treatment, aceclofenac is found to be statistically superior to other NSAIDs.

Clinical Evidence of GI Safety of Aceclofenac
The clinical evidence on the GI safety of aceclofenac based on the type of GI adverse events is mentioned below:

Superior in Terms of Epigastric Discomfort, Dyspepsia and Abdominal Pain
Gastric mucus is important as the first line of defense against luminal irritants. Studies show that about 40% of the individuals who take one NSAID can present gastric erosion. According to other studies, this prevalence can reach even
100 %, within the first month of treatment. Gastrointestinal tolerance of aceclofenac is confirmed endoscopically in 42 healthy subjects by Yanagawa et al. The authors demonstrated that aceclofenac is a promising NSAID with low potential for injuring the human gastroduodenal mucosa. They endoscopically compared mucosal damage between aceclofenac and diclofenac for 2 weeks. There was a significantly lower incidence of gastric mucosal lesions with aceclofenac as compared to diclofenac (20 % vs. 50 %, P < 0.05). A large prospective, multicenter observational study complying with the safety assessment of marketed medicines (SAMM) guidelines was conducted on 10142 patients (aceclofenac n=7890; diclofenac n=2252). They were prescribed aceclofenac 100 mg bid or diclofenac 75 mg bid for 12 months. The risk of GI adverse events like dyspepsia, nausea, abdominal pain and diarrhoea was 1.3, 1.5, 1.8, and 2.5-fold higher respectively among the diclofenac-treated patients. The study established that aceclofenac was not only significantly better tolerated, but also showed greater treatment acceptability and less treatment discontinuation as compared to diclofenac (100 mg BID). A consequence of prostaglandin depletion is to create an environment that is conducive to peptic ulcer formation and serious GI complications. The rates of withdrawal from treatment due to adverse events are reported to be significantly lower after aceclofenac. In comparison to ketoprofen it was 2.3 vs. 13.4 %; P < 0.01 and 8.2 vs. 16.4 %; P=0.027 in comparison to diclofenac. All this clinical evidence indicates that aceclofenac has better compliance and is a patient-friendly NSAID with good GI tolerability and safety.

**Figure 2. A) % of Patients with Gastric Damage, B) Effect of Diclofenac and Aceclofenac on Hexosamine Content**

Multiple studies have shown that aceclofenac has a better GI tolerability profile in comparison to other NSAIDs like diclofenac, indomethacin, ketoprofen, and piroxicam. GI symptoms are also the major cause of withdrawal in the treatment of NSAIDs, thereby affecting the clinical outcome of an inflammatory condition. The rates of withdrawal from treatment due to adverse events are reported to be significantly lower after aceclofenac. In comparison to ketoprofen it was 2.3 vs. 13.4 %; P < 0.01 and 8.2 vs. 16.4 %; P=0.027 in comparison to diclofenac. All this clinical evidence indicates that aceclofenac has better compliance and is a patient-friendly NSAID with good GI tolerability and safety.

**Figure 4. Tolerability of Aceclofenac in Various NSAIDs A) Aceclofenac vs. Diclofenac B) Aceclofenac vs. Diclofenac C) Aceclofenac vs. Diclofenac (D) Aceclofenac vs. Indomethacin (E) Aceclofenac vs. Ketoprofen (F) Aceclofenac vs. Piroxicam**

A large prospective, multicenter observational study complying with the safety assessment of marketed medicines (SAMM) guidelines was conducted on 10142 patients (aceclofenac n=7890; diclofenac n=2252). They were prescribed aceclofenac 100 mg bid or diclofenac 75 mg bid for 12 months. The risk of GI adverse events like dyspepsia, nausea, abdominal pain and diarrhoea was 1.3, 1.5, 1.8, and 2.5-fold higher respectively among the diclofenac-treated patients. The study established that aceclofenac was not only significantly better tolerated, but also showed greater treatment acceptability and less treatment discontinuation as compared to diclofenac. A consequence of prostaglandin depletion is to create an environment that is conducive to peptic ulcer formation and serious GI complications. Non-selective NSAIDs like...
diclofenac, piroxicam and ketorolac are more prone to ulcer formation as well as bleeding. While COX-2 selective agents are associated with fewer GI ulcer complications, there is still an increased risk of upper gastrointestinal complications (UGIC). It is recommended by the American College of Physicians that patients with previous ulcer bleeding who require an NSAID, be treated with the combination of a PPI and a COX-2 inhibitor. But, a study reported that combination therapy with NSAIDs and proton pump inhibitors (PPIs) for two weeks causes small intestinal mucosal injury in 68% of healthy adults therefore, the mucosal injury induced by NSAIDs is not prevented by PPIs. Using GI friendly NSAID, with minimal need for PPI is thus a preferable choice. Pareek et al. conducted a 6-week, multicenter clinical study comparing aceclofenac with diclofenac, to assess their GI safety and tolerability in 591 individuals with knee osteoarthritis. The incidence and severity of GI adverse events, as well as the use of gastroprotective medications, were the major endpoints in this study. Throughout the trial, the cumulative sum of GI events in the aceclofenac treatment group was considerably lower than in the diclofenac treatment group (aceclofenac: 163 versus diclofenac: 210; $P < 0.001$). As the incidence of GI AEs was lower in the aceclofenac group, the consumption of GPAs (gastroprotective agents) was also significantly lower compared to the diclofenac group ($P < 0.001$ at all visits). The authors also observed that the need for gastroprotective agents (GPAs) increased with the increase in the duration of NSAID treatment, so their use is advised for a short period.

In a study by Grau et al. it was found that the acute gastric ulcerogenic activity of aceclofenac was about 2, 4 and 7-fold lesser than that of naproxen, diclofenac or indomethacin, respectively. This study further substantiated the safety profile of aceclofenac.

**Minimal Risk of Upper GI Bleeding/Complications**

It is reported that about 1 to 2% of NSAID users experience serious complications during treatment. Patients with a history of GI injury are at a higher risk for GI complications. A prospective observational study found that bleeding complications occurred without typical ulcer symptoms (epigastric pain or dyspepsia) in up to 80% of affected patients. The risk of upper gastrointestinal complications (UGIC) is a serious public health concern.

Within the European Community's Seventh Framework Programme, the safety of non-steroidal anti-inflammatory drugs [SOS] project aimed to develop decision models for regulatory and clinical use of individual NSAIDs according to their GI and cardiovascular safety. Castellsague et al conducted a systematic review and meta-analysis of 28 observational studies to provide relative risk (RR) of UGIC of individual NSAIDs. The authors found that out of 16 NSAIDs compared, Pooled RR of UGIC was lowest with aceclofenac (1.43; 95% CI 0.65, 3.15) and highest for ketorolac (11.50; 95% CI 5.56, 23.78). The commonly used NSAIDs like diclofenac and piroxicam also had a higher relative risk (diclofenac; 3.34; 95% CI 2.79, 3.99, piroxicam; 7.43; 95% CI 5.19, 10.63) (Figure 5). A summary of various clinical studies showing GI safety and tolerability of aceclofenac in comparison to NSAIDs is given in Table 1.

![Figure 5. Relative Risk of Upper Gastrointestinal Complications](image-url)
In conclusion, clinical studies have proven that aceclofenac is well-tolerated amongst the NSAIDs, with a lower incidence of GI adverse effects, reduced withdrawal rate, the minimal need for gastroprotective agents and hence greater patient compliance.[48] It is always advisable to respect recommended daily dose and duration of treatment and avoid its usage in high-risk patients.

Cardiac Safety

Several pathways have been hypothesised to elucidate the pathophysiology of cardiac events caused by the use of NSAIDs. The most significant mechanism is disturbed equilibrium between prostacyclin (PGI2) and thromboxane A2 (TXA2). PGI2, produced by the COX-2 enzyme, is a vasodilator and inhibitor of platelet aggregation. In contrast, thromboxane A2 (TXA2), produced by the COX-1 enzyme is a vasoconstrictor and mediates platelet aggregation (Figure 6). The key strategy for preserving homeostasis between TXA2 and PGI2 is to balance COX-1 and COX-2 inhibition. This approach will help to reduce the number of cardiac incidents caused by NSAIDs.[47]

Several meta-analyses, randomized controlled trials, and cohort studies have reported the cardiovascular risk associated with the use of NSAIDs. Some studies have reported increased risk even with short term NSAID use of < 7 days [48], CV risk due to NSAIDs is a major concern in elderly patients and those who have co-morbidities. Using NSAIDs with minimal cardiac risk is always given a preference.

Clinical Evidence of Cardiac Safety of Aceclofenac

In data from four European countries (Netherlands, Italy, Germany and United Kingdom) covering over 10 million patients, the researchers looked at the association between the risk of hospitalization for heart failure and the use of 27 different NSAIDs, including 23 traditional NSAIDs and four selective COX-2 inhibitors. The meta-analysis in this study showed a significant association between the risks of heart failure with multiple NSAIDs. Pooled odds ratio (95 % CI) observed for different NSAIDs is mentioned in the below table.

<table>
<thead>
<tr>
<th>NSAID</th>
<th>Pooled odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketorolac</td>
<td>1.85 (1.62 to 2.12)</td>
</tr>
<tr>
<td>Etoricox</td>
<td>3.67 (1.39 to 9.60)</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>1.55 (1.31 to 1.83)</td>
</tr>
<tr>
<td>Nabumetone</td>
<td>1.48 (1.07 to 2.06)</td>
</tr>
<tr>
<td>Rofecoxib</td>
<td>1.48 (1.25 to 1.49)</td>
</tr>
<tr>
<td>Piroxicam</td>
<td>1.28 (1.16 to 1.42)</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>1.21 (1.07 to 1.37)</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>1.20 (1.07 to 1.39)</td>
</tr>
<tr>
<td>Nimesulide</td>
<td>1.19 (1.14 to 1.23)</td>
</tr>
<tr>
<td>Naproxen</td>
<td>1.18 (1.00 to 1.40)</td>
</tr>
<tr>
<td>Meloxicam</td>
<td>1.04 (0.93 to 1.16)</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>1.04 (0.96 to 1.12)</td>
</tr>
<tr>
<td>Diclofenac Comb</td>
<td>1.02 (0.85 to 1.22)</td>
</tr>
<tr>
<td>Aceclofenac</td>
<td>0.97 (0.73 to 1.38)</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>0.96 (0.90 to 1.02)</td>
</tr>
</tbody>
</table>

NSAIDs increased the risk of hospital admission for heart failure, even if used at medium doses. An interesting
observation regarding aceclofenac within the analyses was that it showed less risk of heart failure (pooled odds ratio 0.97 (0.73 to 1.28). The risk of hospitalization due to prior heart failure was also lesser with aceclofenac as compared to other NSAIDs.[49]

An independent research project funded by the European Commission, The Safety Of Non-Steroidal anti-inflammatory drugs (SOS) project, was designed to assess and compare the risk of cardiovascular and gastrointestinal events in users of NSAIDs and coxibs. This study found that 10 NSAIDs, including ketorolac, indomethacin, etoricoxib, rofecoxib, diclofenac and their combinations, piroxicam, ibuprofen, meloxicam, and nimesulide, significantly increased the risk of MI. Kterrorolac was found to have the highest risk of MI, with an adjusted odds ratio of 2.06. (1.83 to 2.32) and was correlated with COX-2 potency, but not restricted to coxibs. Aceclofenac was found to increase MI risk non-significantly, and the adjusted odds ratio was 1.04 (0.90 to 1.19), which was less in comparison to 17 NSAIDs. (Figure 7).[50]

It is reported that hypertension is the most common comorbidity in osteoarthritis patients. Estimates of the prevalence of hypertension in populations of adults with OA range from 32 to 81 %.[51] While prescribing the NSAIDs to these patients, minimal/no risk is shown to be preferred. Many clinical studies and PMS data have shown that aceclofenac does not interfere with blood pressure. In a comparative clinical study of aceclofenac versus etoricoxib to assess the incidence of hypertension in rheumatoid arthritis patients, it was discovered that aceclofenac does not raise diastolic or systolic blood pressure whereas etoricoxib caused an increase in both systolic and diastolic blood pressure after 24 weeks, with an increase in DBP being statistically significant.[52]

In nutshell, the cardiovascular safety of non-selective and COX-2 selective inhibitors is controversial. An NSAID with good efficacy, good GI tolerability and minimal adverse cardiovascular effects is, therefore, a profile preferred by physicians, especially in long term usage. Aceclofenac is an anti-inflammatory and analgesic drug with preferential COX-2 inhibition, with minimal GI as well as CV risk.

Other Safety Parameters
Renal Safety
Besides GI and CV, the risk of renal complication is another concern with NSAID use. Renal prostaglandins along with other mediators help to maintain normal renal homeostasis, and when prostaglandins are inhibited by the use of NSAIDs, optimal renal functions can compensate for this decrease. More significant changes may occur in patients with prior renal dysfunction or reduced perfusion. These patients are at the greatest risk for renal side effects. Although renal events are uncommon, they can have profound consequences if the drug use is not stopped and appropriate care is not initiated. Aceclofenac has the lowest renal risk in a pharmacovigilance report when compared with other NSAIDs like diclofenac, nimesulide, naproxen, piroxicam and meloxicam.[53]

As per the prescribing information of aceclofenac, there is no evidence to modify its dosage in patients with mild renal impairment, but as with other NSAIDs caution should be exercised and renal function should be monitored in these patients. Effects on renal function are usually reversible on withdrawal but, it is contraindicated in moderate to severe renal failure.[54]

Hepatic Safety
Many clinical trials and meta-analyses have found that taking NSAIDs causes an increase in liver markers or liver transaminases.[55] Clinically visible liver impairment caused by NSAIDs is uncommon (one to ten instances per 100,000 prescriptions) and usually manifests as acute hepatitis within one to three months after commencing the medication.[56]

Clinical Evidence of Hepatic Safety of Aceclofenac
Agundez et al assessed the hepatotoxicity of 21 NSAIDs and non-NSAIDs such as acetaminophen. It was observed that seven NSAIDs such as ibuprofen, aspirin, naproxen, nimesulide, diclofenac, piroxicam and sulindac contributed about 99 % of cases of hepatotoxicity. In the non-NSAID group, acetaminophen is the commonest cause of intrinsic hepatotoxicity. Interestingly, aceclofenac showed less than 0.1 % of total cases of liver injury. Also, it was mentioned that crude and adjusted frequencies of aceclofenac were less among 11 NSAIDs[57] (Table 3). In a one-year post-marketing monitoring study to assess the incidence of liver toxicity with aceclofenac, meloxicam, and rofecoxib, Aceclofenac showed the lowest incidence of 0.241, 95 % CI (0.006-1.343).[58]

<table>
<thead>
<tr>
<th>Group</th>
<th>Generic Name</th>
<th>Percentage of Total Cases of Liver Injury</th>
<th>Percentage of Total Cases of Liver Injury</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salicylates</td>
<td>Aspirin</td>
<td>6.9%</td>
<td>12%</td>
</tr>
<tr>
<td></td>
<td>Salicylate</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td>Acetic acid derivatives</td>
<td>Acetylsalicyc</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Acenocin</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Diclofenac</td>
<td>19.5%</td>
<td>34.1%</td>
</tr>
<tr>
<td></td>
<td>Indomethacin</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Ketorolac</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Sulindac</td>
<td>7.1%</td>
<td>12.4%</td>
</tr>
<tr>
<td>Propionic acid derivatives</td>
<td>Dextroprofen</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Ibuprofen</td>
<td>8.4%</td>
<td>14.6%</td>
</tr>
<tr>
<td></td>
<td>Ketoprofen</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Naproxen</td>
<td>6.4%</td>
<td>11.4%</td>
</tr>
<tr>
<td></td>
<td>Oxaproprin</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td>Ethenic acid derivatives</td>
<td>Droxiam</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Meloxicam</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Piroxicam</td>
<td>5.4%</td>
<td>9.3%</td>
</tr>
<tr>
<td></td>
<td>Tenoxicam</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td>Selective COX-2 inhibitors</td>
<td>Celecoxib</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Rofecoxib</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td></td>
<td>Valdecoxib</td>
<td>&lt;0.1%</td>
<td>&lt;0.1%</td>
</tr>
<tr>
<td>Sulfonanilides</td>
<td>Nimesulide</td>
<td>3.3%</td>
<td>5.8%</td>
</tr>
<tr>
<td>Non-NSAID analgesics</td>
<td>Acetaminophen</td>
<td>42.7%</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Methamizole</td>
<td>&lt;0.1%</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 3. Incidence of Liver Injuries by NSAIDs[57]
CONCLUSIONS

Pain and inflammation are the commonly seen signs and symptoms in clinical practice. NSAIDs have become the cornerstone in the management of acute, chronic and other painful inflammatory conditions. In the selection of NSAIDs, safety is an important criterion besides pain relief. Earlier, side effects pertaining to the gastrointestinal tract were mainly looked for in NSAIDs. Currently, cardiovascular risk due to NSAIDs is a major concern, especially in elderly patients and those who have comorbidities. The benefit-risk balance of individual NSAIDs is mainly driven by their GI and CV safety profiles. Aceclofenac has gained a position amongst NSAIDs over the last two decades due to its potent or equivalent anti-inflammatory and analgesic properties as well as favourable safety profile. An independent research project by the European Commission, the Safety Of non-steroidal anti-inflammatory drugs (SOS) project, was designed to assess and compare the risk of GI and CV events in NSAID users. Based on their systematic review and meta-analysis, aceclofenac was found to be the safest.

Acknowledgement

The authors thank Dr Vivek Kumawat & Dr Apurva Jawdekar for their contribution to the literature search & drafting of the manuscript

REFERENCES


[53] Lapeyre-Mestre M, Grolleau S, Montastruc JL. Adverse drug reactions associated with the use of NSAIIDs: a case/noncase analysis of spontaneous reports from the

[54] Aceclofenac 100 mg film-coated Tablets - Summary of Product Characteristics (SPC) - (eMC).


